ALL patients who received Aucatzyl immunotherapy, made from their own T cells, experienced complete remission within three ...

MIAMI, FLORIDA - Hematology researchers from Sylvester Comprehensive Cancer Center and the Miller School of Medicine at the University of Miami are authors or co-authors on more than 70 posters to be ...

AUCATZYL® (obecabtagene autoleucel) approved by US FDA on November 8, ahead of target PDUFA date of November 16; US commercial launch initiatedBLA approval triggers $30m milestone payment to Autolus ...

The technology accurately detects the presence of these gene fusions in acute promyelocytic ... or refractory T-cell ... Why Children With Down Syndrome Have Higher Risk of Leukemia Sep. 25 ...

Obe-cel was designed to increase T-cell persistence and reduce T-cell exhaustion and was shown to improve response rates and survival, particularly in patients with low leukemia burden.

Obecabtagene autoleucel (obe-cel; Aucatzyl) has been approved by the FDA to treat patients with relapsed or refractory B-cell ...

The FDA approved obecabtagene autoleucel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

The FDA approved obecabtagene autoleucel (obe-cel; Aucatzyl) for treating relapsed or refractory B-cell precursor acute ...

This, they concluded, indicates a shared founder clone of chronic and blast phases with different driver mutations and therefore different progressing capacities. This finding was further supported by ...

Acute lymphoblastic leukemia (ALL) is a form of leukemia, or cancer of the white blood cells characterized by ... in a relatively immature (also termed 'blast') state. Science X Daily and the ...

Rong Lu, associate professor of stem cell biology and regenerative medicine, biomedical engineering, medicine, and gerontology at USC, and a Leukemia & Lymphoma Society Scholar Lu is also a member of ...